{
  "source": "PA-Notification-Filspari-Vanrafia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Program\nProgram Number 2025 P 1479-1\nProgram Prior Authorization/Notification\nMedication Filspari™ (sparsentan), Vanrafia™ (atrasentan)\nP&T Approval Date 6/2025\nEffective Date 9/1/2025\n1. Background:\nFilspari (sparsentan) is indicated to slow kidney function decline in adults with primary\nimmunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Vanrafia (atrasentan)\nis indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at\nrisk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.\nVanrafia is approved under accelerated approval based on a reduction of proteinuria. It has not been\nestablished whether Vanrafia slows kidney function decline in patients with IgAN. Continued\napproval for this indication may be contingent upon verification and description of clinical benefit in\na confirmatory clinical trial.\n2. Coverage Criteriaa:\nI. Initial Authorization\nA. Filspari will be approved based upon all of the following criteria:\n1. Diagnosis of primary immunoglobulin A nephropathy (IgAN)\n-AND-\n2. Patient is at risk of disease progression\n-AND-\n3. Used to slow kidney function decline\nAuthorization will be issued for 12 months\nB. Vanrafia will be approved based upon all of the following criteria:\n1. Diagnosis of primary immunoglobulin A nephropathy (IgAN)\n-AND-\n2. Patient is at risk of disease progression\n-AND-\n3. Used to reduce proteinuria\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months\nII. Reauthorization\n1. Filspari or Vanrafia will be approved based on the following criterion:\na. Documentation of positive clinical response\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n",
    "al regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Medical Necessity and Supply limits may be in place.\n4. References:\n1. Filspari [package insert]. San Diego, CA: Traverse Therapeutics, Inc; April 2025.\n2. Vanrafia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April\n2025.\n3. KDIGO 2021 Glomerular Diseases Guideline. October 2021; 100 (4S).\nProgram Prior Authorization/Notification – Filspari, Vanrafia\nChange Control\n6/2025 New program\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}